Our mission is to spearhead humanity’s process of enhancing itself in an act of its own creation by focusing on mental health & longevity, fueled by AI. We enable people to live longer, healthier and happier lives.
Our name is derived from ATAI, the ancient African goddess of creation. Homo Sapiens has started to emerge in Africa approximately 300,000 years ago and the development is now coming full circle. We are right at the tipping point for the next evolutionary step: Modern science combined with state-of-the-art technology like artificial intelligence and big data solutions is about to dramatically extend our lifespan and enhance our physical and mental abilities.
We aim to become the leading biotech company globally in this final frontier for humanity as we know it by developing and acquiring promising therapeutics focusing on longevity and mental wellbeing.
Following a decentralized platform approach with a relentless focus on execution, we incubate and acquire high-impact compounds with the goal to get to POC in record speed and with a higher likelihood of approval.
We have a special passion for psychedelics. Our holding COMPASS Pathways is developing a psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression. Several academic studies – the first dating back to the 1950s – have suggested that psilocybin therapy provides immediate and sustained reductions in depression and other illnesses. COMPASS has just started its phase IIb trial in the US, Canada and Europe, which is the largest trial ever done with a psychedelic substance.
Our portfolio company Perception Neuroscience develops arketamine for neuropsychiatric diseases. Arketamine belongs to a new generation of glutamate receptor modulators with the potential for rapid acting antidepressant (RAAD) activity and anti-suicidal effects. Ketamine, as described in the journal Science “is arguably the most important discovery in half a century” of research in depression, and arketamine is anticipated to differentiate robustly from other development stage RAAD’s on both efficacy and safety.
ATAI Life Sciences AG has been founded by Apeiron Investment Group Ltd, the family office of Christian Angermayer.